A pharmacogenetic study of response to a 5-lipoxygenase inhibitor in a Phase II clinical trial.

被引：0
|
作者：
Lewitzky, S
Barnes, G
Garg, P
Metivier, J
Chang, M
Rosengren, B
Meyer, J
机构：
[1] Millennium Pharmaceut Inc, Dept Clin Dev, Cambridge, MA USA
[2] Millennium Pharmaceut Inc, Dept Mol & Cellular Pharmacol, Cambridge, MA USA
[3] Millennium Pharmaceut Inc, Dept Mol Epidemiol, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF HUMAN GENETICS | 2003年 / 73卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
1288
引用
收藏
页码：390 / 390
页数：1
相关论文
共 50 条
  • [31] A-78773 - A SELECTIVE, POTENT 5-LIPOXYGENASE INHIBITOR
    BELL, RL
    BROOKS, DW
    YOUNG, PR
    LANNI, C
    STEWART, AO
    BOUSKA, J
    MALO, PE
    CARTER, GW
    JOURNAL OF LIPID MEDIATORS, 1993, 6 (1-3): : 259 - 264
  • [32] PHARMACOLOGICAL AND CLINICAL EFFECTS OF LONAPALENE (RS-43179), A 5-LIPOXYGENASE INHIBITOR, IN PSORIASIS
    BLACK, AK
    CAMP, RDR
    MALLET, AI
    CUNNINGHAM, FM
    HOFBAUER, M
    GREAVES, MW
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 95 (01) : 50 - 54
  • [33] Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton
    Collin, M
    Rossi, A
    Cuzzocrea, S
    Patel, NSA
    Di Paola, R
    Hadley, J
    Collino, M
    Sautebin, L
    Thiemermann, C
    JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 76 (05) : 961 - 970
  • [34] Transscleral Iontophoresis of cortcicosteoids: Phase II clinical trial.
    Chauvaud, D
    Behar-Cohen, FF
    Parel, JM
    Renard, G
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S79 - S79
  • [35] Prevalence of 5-Lipoxygenase Expression in Canine Osteosarcoma and the Effects of a Dual 5-Lipoxygenase/Cyclooxygenase Inhibitor on Osteosarcoma Cells In Vitro and In Vivo
    Goupil, R. C.
    Bushey, J. J.
    Peters-Kennedy, J.
    Wakshlag, J. J.
    VETERINARY PATHOLOGY, 2012, 49 (05) : 802 - 810
  • [36] A Practical Synthesis of 5-Lipoxygenase Inhibitor MK-0633
    Gosselin, Francis
    Britton, Robert A.
    Davies, Ian W.
    Dolman, Sarah J.
    Gauvreau, Danny
    Hoerrner, R. Scott
    Hughes, Gregory
    Janey, Jacob
    Lau, Stephen
    Molinaro, Carmela
    Nadeau, Christian
    O'Shea, Paul D.
    Palucki, Michael
    Sidler, Rick
    JOURNAL OF ORGANIC CHEMISTRY, 2010, 75 (12): : 4154 - 4160
  • [37] Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase
    Albert, D
    Zündorf, I
    Dingermann, T
    Müller, WE
    Steinhilber, D
    Werz, O
    BIOCHEMICAL PHARMACOLOGY, 2002, 64 (12) : 1767 - 1775
  • [38] THE IMMUNOSUPPRESSIVE EFFECT OF 5-LIPOXYGENASE INHIBITOR ON LIVER ALLOTRANSPLANTATION IN RATS
    IYOBE, T
    IZUMI, R
    SHIMIZU, K
    TRANSPLANTATION, 1993, 56 (03) : 518 - 523
  • [39] A selective inhibitor of arachidonate 5-lipoxygenase scavenging peroxide activator
    Suzuki, H
    Miyauchi, D
    Yamamoto, S
    BIOCHEMICAL PHARMACOLOGY, 1997, 54 (04) : 529 - 532
  • [40] Synthesis of A-79175: a second generation 5-lipoxygenase inhibitor
    Dickman, D. A.
    Ku, Y.-Y.
    Morton, H. E.
    Chemburkar, S. R.
    Tetrahedron: Asymmetry, 8 (11):
12345